Given the short duration of these trials (Table 1)
, survival has generally not been addressed. Barst et al13
did show that IV prostacyclin was associated with a significant survival benefit, with no mortality at 12 weeks vs 20% in the control group. Two groups23–24
have recently reported long-term survival during IV prostacyclin therapy. In 162 WHO class III/IV patients with PPH treated with IV prostacyclin for a mean of 3 years, McLaughlin et al23
showed improved survival of 88%, 76%, and 63% at 1, 2, and 3 years, respectively, vs predicted survival of 59%, 46%, and 35% based on hemodynamic severity, using an equation derived from the National Institutes of Health database.25–26
Sitbon et al24
reported nearly identical survival of 85%, 70%, and 63% at 1, 2, and 3 years, respectively, in 178 IV prostacyclin-treated patients with PPH.